Abstract: OBJECTIVE To systematically evaluate the pharmacoeconomic characteristics of human papillomavirus(HPV) vaccine on preventing cervical cancer in Chinese women. METHODS A global literature search from inception to February, 2020 was performed using database such as PubMed, EMbase, CNKI, Wanfang Data, CQVIP and China Biology Medicine(CBM) to collect pharmacoeconomic studies about HPV vaccine preventing cervical cancer in Chinese women. Two reviewers screened literature and collected data independently in compliance with the standards. The Consolidated Health Economic Evaluation Reporting Standards(CHEERS) and Quality of Health Economic Studies(QHES) were applied to evaluate the quality of the literature enrolled, then descriptive analysis was performed. RESULTS A total of 15 studies were included, 4 being cost-effectiveness studies, and the remaining 11 being cost-utility studies. Nine studies were from mainland China, 5 were from Taiwan China, and 1 was from Hong Kong China, the quality of literature was high. Compared with cervical cancer screening only and no intervention, HPV vaccination combines with cervical cancer screening was more cost-effective in women with no history of HPV infection. However, the economic results were inconsistent between different types of HPV vaccines. CONCLUSION It is recommended that the HPV vaccine should be included in the medical insurance and relevant financial investment should be increased. Further studies on the economic results between different types of HPV vaccine are also recommended.